Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dittrich

Showing results (191-200 of 229) with videos related to

Pageof 23
Sort By:
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
European Journal of Heart Failure|March 16, 2010
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot studyMarco Metra, John G Cleland, Beth Davison Weatherley, et al.
American Heart Journal|February 27, 1999
Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation InvestigatorsH C Dittrich, L A Pearce, R W Asinger, et al.
Cureus|July 11, 2024
Leaving Against Medical Advice: Current Problems and Plausible SolutionsShamma S Alhajeri, Ibrahim A Atfah, Ali M Bin Yahya, et al.
American Heart Journal|July 5, 2021
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerationsThomas J Povsic, Timothy D Henry, E Magnus Ohman, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
Heart Rhythm|April 26, 2016
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SRJonathan P Piccini, Edward L C Pritchett, Beth A Davison, et al.
Journal of the American College of Cardiology|May 7, 2011
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function)Adriaan A Voors, Howard C Dittrich, Barry M Massie, et al.
JACC. Heart Failure|May 9, 2015
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF StudiesBeth A Davison, Marco Metra, Gad Cotter, et al.
European Journal of Heart Failure|April 27, 2016
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortalityBeth A Davison, Marco Metra, Stefanie Senger, et al.
Pageof 23

Showing results (191-200 of 229) with videos related to

Sort By:
Pageof 23
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
European Journal of Heart Failure|March 16, 2010
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot studyMarco Metra, John G Cleland, Beth Davison Weatherley, et al.
American Heart Journal|February 27, 1999
Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation InvestigatorsH C Dittrich, L A Pearce, R W Asinger, et al.
Cureus|July 11, 2024
Leaving Against Medical Advice: Current Problems and Plausible SolutionsShamma S Alhajeri, Ibrahim A Atfah, Ali M Bin Yahya, et al.
American Heart Journal|July 5, 2021
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerationsThomas J Povsic, Timothy D Henry, E Magnus Ohman, et al.
Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.
Heart Rhythm|April 26, 2016
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SRJonathan P Piccini, Edward L C Pritchett, Beth A Davison, et al.
Journal of the American College of Cardiology|May 7, 2011
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function)Adriaan A Voors, Howard C Dittrich, Barry M Massie, et al.
JACC. Heart Failure|May 9, 2015
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF StudiesBeth A Davison, Marco Metra, Gad Cotter, et al.
European Journal of Heart Failure|April 27, 2016
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortalityBeth A Davison, Marco Metra, Stefanie Senger, et al.
Pageof 23